Physician profile
Kendra K Watts
NPI 1689927667
$3,773.69
in general payments reported to CMS, 2019-2025
21 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2023: $262 · 2024: $1,668 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,648.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $584.79 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $445.44 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $397.09 | 2023-2025 | Rexulti |
| Abbvie INC. | $387.71 | 2023-2025 | |
| Axsome Therapeutics, INC. | $290.65 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $257.42 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $208.27 | 2023-2025 | |
| Lundbeck LLC | $196.65 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.94 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $158.25 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $110.76 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $104.97 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $84.82 | 2023-2024 | Gattex |
| Amgen INC. | $77.75 | 2023-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $77.25 | 2024-2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $66.06 | 2021 | |
| Paratek Pharmaceuticals, INC. | $37.95 | 2024-2025 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $28.33 | 2024 | Zoryve, Livalo |
| Dexcom, INC. | $25.01 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $20.47 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $18.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.